Literature DB >> 3264161

Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules.

F Darchen1, D Scherman, C Desnos, J P Henry.   

Abstract

1-Methyl-4-phenylpyridinium (MPP+), an active metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine which induces Parkinson's disease in man, is a substrate of the monoamine uptake system of chromaffin granules. It is accumulated without chemical modification by bovine chromaffin granule membrane vesicles in the presence of ATP. The transport is saturable and is characterized by a Km value of 0.8 microM at pH 8.0, similar to that of serotonin (5-HT). Transport occurs through the monoamine transporter since it is competitively inhibited by 5-HT and since MPP+ competitively inhibits [3H]5-HT uptake. Moreover, [3H]MPP+ uptake is blocked by the monoamine transporter inhibitors tetrabenazine and reserpine. Finally, MPP+ efficiently displaces [3H]reserpine and [3H]dihydrotetrabenazine from their binding sites on the transporter. In the pH range 6-8, the Km for [3H]MPP+ uptake and the EC50 of MPP+ for the displacement of [3H]dihydrotetrabenazine decrease logarithmically with the pH. MPP+ is the first quaternary ammonium salt shown to be a substrate of the monoamine transporter and it has the same pH-dependency as monoamines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264161     DOI: 10.1016/0006-2952(88)90621-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Functionally important carboxyls in a bacterial homologue of the vesicular monoamine transporter (VMAT).

Authors:  Dana Yaffe; Ariela Vergara-Jaque; Yonatan Shuster; Dina Listov; Sitaram Meena; Satinder K Singh; Lucy R Forrest; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 2.  Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function.

Authors:  H Varoqui; J D Erickson
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 3.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 4.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

5.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Seth D Norrholm; Peter A Crooks
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

6.  Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats.

Authors:  M Kujacic; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

7.  Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.

Authors:  Yelena Ugolev; Tali Segal; Dana Yaffe; Yael Gros; Shimon Schuldiner
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

Review 8.  Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action.

Authors:  Caline S Karam; Jonathan A Javitch
Journal:  Adv Pharmacol       Date:  2017-10-25

9.  Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.

Authors:  Zachary Freyberg; Mark S Sonders; Jenny I Aguilar; Takato Hiranita; Caline S Karam; Jorge Flores; Andrea B Pizzo; Yuchao Zhang; Zachary J Farino; Audrey Chen; Ciara A Martin; Theresa A Kopajtic; Hao Fei; Gang Hu; Yi-Ying Lin; Eugene V Mosharov; Brian D McCabe; Robin Freyberg; Kandatege Wimalasena; Ling-Wei Hsin; Dalibor Sames; David E Krantz; Jonathan L Katz; David Sulzer; Jonathan A Javitch
Journal:  Nat Commun       Date:  2016-02-16       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.